CMS Study

  • Research type

    Research Study

  • Full title

    NORDIC (and UK) STUDY OF THE CEREBELLAR MUTISM SYNDROME (CMS) IN CHILDREN WITH BRAIN TUMOURS OF THE POSTERIOR FOSSA

  • IRAS ID

    210149

  • Contact name

    Conor Mallucci

  • Contact email

    conor.mallucci@alderhey.nhs.uk

  • Sponsor organisation

    Alder Hey Children's NHS Foundation Trust

  • Duration of Study in the UK

    3 years, months, days

  • Research summary

    Central nervous system (CNS) tumours constitute 25% of all childhood cancers, and more than half of these are located in the cerebellum. One of the most troublesome late effects after operation for such a tumour is the cerebellar mutism syndrome (CMS) which is seen in up to 25% of children after surgery. It is characterized by mutism, hypotonia, ataxia and irritability, and the exact causes have yet to be identified.\n\nThe purposes of this study are to uncover: 1) which surgical methods are least likely to cause the CMS and if there is a difference in risk between primary surgery and re-operation, 2) which patients may be genetically predisposed to developing the CMS, 3) the effect of corticosteroids, and 4) differences in incidence and clinical course of the CMS according to tumour type, comorbidities, handedness and treatments.\n\nWe hope that the results will contribute to an overall reduction in incidence of the CMS and lead to international harmonization of the treatment of these patients.

  • REC name

    North West - Liverpool Central Research Ethics Committee

  • REC reference

    16/NW/0633

  • Date of REC Opinion

    12 Apr 2017

  • REC opinion

    Further Information Favourable Opinion